Clinical Trial Update: A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for rAAV2-ND4 delivered via a single intravitreal injection in Leber hereditary optic neuropathy, currently in Phase 2/Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Hereditary Optic Neuropathy

Drugs mentioned

• rAAV2-ND4 (rAAV2-ND4)

Snippet

Sponsor: Huazhong University of Science and Technology | Conditions: Leber Hereditary Optic Neuropathy | Phase 2, Phase 3 | Status: UNKNOWN